Q1 Earnings Estimate for SYRE Issued By Leerink Partnrs

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Spyre Therapeutics in a report issued on Tuesday, April 8th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per share of ($0.83) for the quarter. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Spyre Therapeutics' current full-year earnings is ($4.46) per share. Leerink Partnrs also issued estimates for Spyre Therapeutics' Q2 2025 earnings at ($0.83) EPS, Q3 2025 earnings at ($0.84) EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($3.35) EPS and FY2026 earnings at ($3.18) EPS.

Other equities research analysts have also recently issued research reports about the stock. Wolfe Research initiated coverage on shares of Spyre Therapeutics in a research report on Tuesday, March 18th. They set an "outperform" rating and a $27.00 price target for the company. Wedbush reiterated an "outperform" rating and set a $65.00 target price on shares of Spyre Therapeutics in a research report on Monday, January 13th. Leerink Partners initiated coverage on shares of Spyre Therapeutics in a report on Tuesday, April 8th. They set an "outperform" rating and a $45.00 price objective for the company. Finally, The Goldman Sachs Group upgraded Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, February 18th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $49.57.

Spyre Therapeutics Stock Down 3.3 %

NASDAQ:SYRE traded down $0.43 during trading hours on Thursday, hitting $12.59. 184,077 shares of the stock were exchanged, compared to its average volume of 585,332. The company has a market capitalization of $758.64 million, a P/E ratio of -1.69 and a beta of 3.05. Spyre Therapeutics has a twelve month low of $10.91 and a twelve month high of $40.49. The company's 50 day moving average is $18.25 and its two-hundred day moving average is $24.15.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.08.

Institutional Investors Weigh In On Spyre Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of SYRE. GF Fund Management CO. LTD. acquired a new stake in Spyre Therapeutics during the 4th quarter valued at $29,000. Huntington National Bank bought a new stake in shares of Spyre Therapeutics during the fourth quarter worth approximately $34,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Spyre Therapeutics during the 4th quarter worth approximately $46,000. GAMMA Investing LLC acquired a new position in Spyre Therapeutics in the 1st quarter valued at $70,000. Finally, KLP Kapitalforvaltning AS bought a new position in Spyre Therapeutics during the 4th quarter worth $182,000. 80.39% of the stock is owned by institutional investors.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).